Legend Biotech Corporation (NASDAQ:LEGN) Q3 2023 Earnings Call Transcript

Operator: Thank you. One moment for our next question. And our next question coming from the line of Sami Corwin with William Blair. Your line is open.

Sami Corwin: Good morning. Thanks for taking my question. Given you plan on over-enrolling CARTITUDE-5 now, will that delay when we should expect data from that trial? And then do you plan on providing any revenue guidance for CARVYKTI at the beginning of 2024? Thanks.

Ying Huang: Thanks for the question, Sami. So on the first question, no, we don’t expect any delay, because like I mentioned, we are pretty much on track to close all the ex-US enrollment for CARTITUDE-5, which is the majority of the patients by end of this year. That’s exactly according to our plan. And then we’re only over-enrolling in the US next quarter just to make sure that we have a representative percentage of US patients in this trial. So at this point, we do not expect any delay in terms of readout of CARTITUDE-5. And then on product guidance, we’re not really giving product guidance for the year of 2024 because our partner, J&J, has this policy of not providing product-specific guidance. So, unfortunately, we will not be in a position to provide you with guidance for CARVYKTI sales.

Sami Corwin: Got you. Thank you.

Ying Huang: Thank you.

Operator: Thank you. And at this time, we have no further questions in the queue. Ladies and gentlemen, this concludes today’s conference call. Thank you all for your participation and you may now disconnect.